Revolution Medicines, Inc. (RVMD)
- Previous Close
38.17 - Open
38.51 - Bid 38.31 x 100
- Ask 38.39 x 300
- Day's Range
37.90 - 39.25 - 52 Week Range
15.44 - 40.63 - Volume
1,266,940 - Avg. Volume
1,420,930 - Market Cap (intraday)
6.324B - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-3.84 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
45.55
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
www.revmed.comRecent News: RVMD
Performance Overview: RVMD
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVMD
Valuation Measures
Market Cap
6.32B
Enterprise Value
4.71B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.10k
Price/Book (mrq)
3.67
Enterprise Value/Revenue
1.03k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.11%
Return on Equity (ttm)
-36.17%
Revenue (ttm)
4.57M
Net Income Avi to Common (ttm)
-484.27M
Diluted EPS (ttm)
-3.84
Balance Sheet and Cash Flow
Total Cash (mrq)
1.7B
Total Debt/Equity (mrq)
5.10%
Levered Free Cash Flow (ttm)
-236.99M